Skip to ContentSkip to Navigation
Rijksuniversiteit Groningenfounded in 1614  -  top 100 university
Over ons Praktische zaken Waar vindt u ons R.A. (Rudolf) de Boer
University Medical Center Groningen

R.A. (Rudolf) de Boer

Cardioloog & Hoofd Experimentele Cardiologie

Publicaties

Obesity and inactivity cluster the strongest risk factor for the development of heart failure in a population-based study

Achieved Ejection Fraction and Effects of Dapagliflozin in Heart Failure With Improved Ejection Fraction

Age-related penetrance of phospholamban p.Arg14del cardiomyopathy

Albuminuria is associated with increased risk of dementia, independent of eGFR: The SCREAM project

Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction

Associations of Genetically Predicted CKD With Urinary Tract Cancer and Lung Cancer: A Mendelian Randomization Analysis

Beyond the gut: Systemic levels of short-chain fatty acids are altered in patients with heart failure

Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation

Cardiovascular Safety in Oncology Clinical Trials: JACC: CardioOncology Primer

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity

Pers/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'